Stemtech Ownership
| STEK Stock | USD 0 0.0002 14.29% |
Stemtech |
Stemtech OTC Stock Ownership Analysis
About 64.0% of the company outstanding shares are owned by corporate insiders. The company had not issued any dividends in recent years. Stemtech Corporation, a stem cell nutrition company, develops science-based products to help the body maintain healthy stem cell physiology in the Americas, Latin America, and Asia. It offers its dietary supplement products under the RCM System, stemrelease3, Stemflo MigraStem, DermaStem, DermaStem Lift, OraStem, and D-Fuze brands. Stemtech Corp operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.The quote for Stemtech is listed on Over The Counter exchange (i.e., OTC), and the entity is not required to meet listing requirements such as those found on the Nasdaq, NYSE, or AMEX exchanges. To find out more about Stemtech contact Charles Arnold at 954 715 6000 or learn more at https://www.stemtech.com.Stemtech Outstanding Bonds
Stemtech issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Stemtech uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Stemtech bonds can be classified according to their maturity, which is the date when Stemtech has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| STLA 1711 29 JAN 27 Corp BondUS85855CAA80 | View | |
| STLA 2691 15 SEP 31 Corp BondUS85855CAB63 | View | |
| STLA 5625 12 JAN 28 Corp BondUS85855CAD20 | View | |
| STLA 6375 12 SEP 32 Corp BondUS85855CAE03 | View |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetOther Information on Investing in Stemtech OTC Stock
Stemtech financial ratios help investors to determine whether Stemtech OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Stemtech with respect to the benefits of owning Stemtech security.